Literature DB >> 21159597

The optimal timing of baseline radiostereometric analysis of uncemented press fit cups.

O Wolf1, J Milbrink, S Larsson, P Mattsson, H Mallmin.   

Abstract

BACKGROUND AND AIMS: The baseline radiostereometric analysis (RSA) is usually performed during the first postoperative week. We investigated the micromotion of two uncemented press fit acetabular cups during the first week after total hip arthroplasty.
MATERIAL AND METHODS: All study patients had unilateral osteoarthritis of the hip and received an uncemented THA combination consisting of a CLS stem and either an Allofit or an Interop acetabular cup. The study group consisted of 24 patients who underwent RSA within 1 hour after skin closure, and at 1 and 7 days after surgery.
RESULTS: The upper limit of the 95% confidence interval for micromotion was less than or close to the precision of the method for all studied directions during the first week after surgery. Mean values indicate proximal and medial translation of the uncemented cup at one week.
CONCLUSIONS: We found only minimal micromotion, barely above the precision limit, measured as medial and proximal translations of these uncemented cups. This indicates that the first postoperative RSA measurement following a primary THA with an uncemented press fit ace-tabular cup should be made as early as possible after the first postoperative day.

Entities:  

Mesh:

Year:  2010        PMID: 21159597     DOI: 10.1177/145749691009900413

Source DB:  PubMed          Journal:  Scand J Surg        ISSN: 1457-4969            Impact factor:   2.360


  2 in total

Review 1.  Adherence of hip and knee arthroplasty studies to RSA standardization guidelines. A systematic review.

Authors:  Rami Madanat; Tatu J Mäkinen; Hannu T Aro; Charles Bragdon; Henrik Malchau
Journal:  Acta Orthop       Date:  2014-06-23       Impact factor: 3.717

2.  RSA of the Symax hip stem.

Authors:  Hannu T Aro; Sanaz Nazari-Farsani
Journal:  Acta Orthop       Date:  2020-05-12       Impact factor: 3.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.